Financial Comparison: InVivo Therapeutics Holdings Corp. (NVIV) & Its Peers

InVivo Therapeutics Holdings Corp. (OTCMKTS: NVIV) is one of 86 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its peers? We will compare InVivo Therapeutics Holdings Corp. to similar businesses based on the strength of its risk, profitability, earnings, valuation, dividends, institutional ownership and analyst recommendations.

Earnings & Valuation

This table compares InVivo Therapeutics Holdings Corp. and its peers top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
InVivo Therapeutics Holdings Corp. N/A N/A -1.47
InVivo Therapeutics Holdings Corp. Competitors $2.13 billion $221.25 million -29.81

InVivo Therapeutics Holdings Corp.’s peers have higher revenue and earnings than InVivo Therapeutics Holdings Corp.. InVivo Therapeutics Holdings Corp. is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings for InVivo Therapeutics Holdings Corp. and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InVivo Therapeutics Holdings Corp. 0 1 0 0 2.00
InVivo Therapeutics Holdings Corp. Competitors 271 1874 3365 108 2.59

InVivo Therapeutics Holdings Corp. presently has a consensus target price of $6.00, suggesting a potential upside of 380.00%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.12%. Given InVivo Therapeutics Holdings Corp.’s higher probable upside, equities research analysts plainly believe InVivo Therapeutics Holdings Corp. is more favorable than its peers.

Profitability

This table compares InVivo Therapeutics Holdings Corp. and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InVivo Therapeutics Holdings Corp. N/A -225.78% -177.84%
InVivo Therapeutics Holdings Corp. Competitors -303.87% -36.00% -12.89%

Institutional & Insider Ownership

51.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

InVivo Therapeutics Holdings Corp. has a beta of 3.27, indicating that its stock price is 227% more volatile than the S&P 500. Comparatively, InVivo Therapeutics Holdings Corp.’s peers have a beta of 1.52, indicating that their average stock price is 52% more volatile than the S&P 500.

Summary

InVivo Therapeutics Holdings Corp. peers beat InVivo Therapeutics Holdings Corp. on 8 of the 11 factors compared.

About InVivo Therapeutics Holdings Corp.

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Receive News & Ratings for InVivo Therapeutics Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics Holdings Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply